| Authors: |
Galsky MD; Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu., Mantia C; Dana-Farber Cancer Institute, Boston, MA, USA., Bowden M; Flare Therapeutics Inc., Cambridge, MA, USA., Bellmunt J; Dana-Farber Cancer Institute, Boston, MA, USA., Garmezy B; Sarah Cannon Research Institute, Nashville, TN, USA., Iyer G; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Petrylak DP; Smilow Cancer Hospital, Yale New Haven Health, New Haven, CT, USA., Rasco D; START Center for Cancer Research, San Antonio, TX, USA., Gupta S; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Rodriguez-Rivera I; NEXT Oncology, San Antonio, TX, USA., Mikhailov Y; Flare Therapeutics Inc., Cambridge, MA, USA., Joshi A; Flare Therapeutics Inc., Cambridge, MA, USA., Nguyen PA; Flare Therapeutics Inc., Cambridge, MA, USA., Kakrecha B; Flare Therapeutics Inc., Cambridge, MA, USA., Tepper J; Flare Therapeutics Inc., Cambridge, MA, USA., Costa AM; Flare Therapeutics Inc., Cambridge, MA, USA., McCrone C; Flare Therapeutics Inc., Cambridge, MA, USA., Rossi AP; Flare Therapeutics Inc., Cambridge, MA, USA., Mertz JA; Flare Therapeutics Inc., Cambridge, MA, USA., Gjini E; Flare Therapeutics Inc., Cambridge, MA, USA., Meyers ML; Flare Therapeutics Inc., Cambridge, MA, USA., Milowsky MI; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Gao X; Massachusetts General Hospital Cancer Center, Boston, MA, USA. |
